Trial Profile
A Phase III, Randomized, Multi-Center, Double-Blind, Global Study to Determine the Efficacy and Safety of Durvalumab in Combination With and Following Chemoradiotherapy Compared to Chemoradiotherapy Alone for Treatment in Women With Locally Advanced Cervical Cancer
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 06 Dec 2023
Price :
$35
*
At a glance
- Drugs Durvalumab (Primary) ; Carboplatin; Cisplatin
- Indications Adenocarcinoma; Adenosquamous carcinoma; Cervical cancer; Squamous cell cancer
- Focus Registrational; Therapeutic Use
- Acronyms CALLA
- Sponsors AstraZeneca
- 01 Dec 2023 Primary endpoint has not been met. (The efficacy of durvalumab + SoC CCRT compared to placebo + SoC CCRT in terms of Progression-Free Survival (PFS)) , according to Results published in the Lancet Oncology
- 01 Dec 2023 Results published in the Lancet Oncology
- 06 Sep 2023 This trial has been completed in Poland, according to European Clinical Trials Database record.